<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "chimeric antigen receptor" OR "CAR T" OR "CAR-"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Impaired tumor death receptor signaling drives resistance to CAR T cell therapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/627562v1">Link</a></p><p><b>Date:</b> 2019-05-05</p><p><b>Authors:</b> Nathan Singh ... Marco Ruella</p><p><b>Downloads:</b> 1273</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Cellular immunotherapy using T cells engineered to express chimeric antigen receptors targeting CD19 (CART19) leads to long-term remission in patients with B-cell malignancies.  Unfortunately, a significant fraction of patients demonstrate primary resistance to CART19 or experience relapse after achieving remission.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Illness-related suffering and need for palliative care in Rohingya refugees and caregivers in Bangladesh: A cross-sectional study.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32126076">Link</a></p><p><b>Date:</b> 03/03/2020</p><p><b>Authors:</b> Megan Doherty ...  Farzana Khan</p><p><b>Journal:</b> PLoS Med.</p><p><b>IF (7 or above):</b> 9.39</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Despite recognition that palliative care is an essential component of any humanitarian response, serious illness-related suffering continues to be pervasive in these settings.  There is very limited evidence about the need for palliative care and symptom relief to guide the implementatio ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Functional effects of chimeric antigen receptor co-receptor signaling domains in human Tregs</h4><p><a href="https://www.biorxiv.org/content/10.1101/749721v1">Link</a></p><p><b>Date:</b> 2019-08-29</p><p><b>Authors:</b> Nicholas A.J. Dawson ... Megan K Levings</p><p><b>Downloads:</b> 781</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Antigen-specific regulatory T cells (Tregs) engineered with chimeric antigen receptor (CARs) are a potent immunosuppressive cellular therapy in multiple disease models.  To date the majority of CAR Treg studies employed second generation CARs, encoding a CD28 or 4-1BB co-receptor signaling domain and CD3zeta, but it was not known if this CAR design was optimal for Tregs.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Evaluation of a very brief pedometer-based physical activity intervention delivered in NHS Health Checks in England: The VBI randomised controlled trial.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32142507">Link</a></p><p><b>Date:</b> 03/06/2020</p><p><b>Authors:</b> Wendy Hardeman ...  None None</p><p><b>Journal:</b> PLoS Med.</p><p><b>IF (7 or above):</b> 9.39</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: The majority of people do not achieve recommended levels of physical activity.  There is a need for effective, scalable interventions to promote activity.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting</h4><p><a href="https://www.biorxiv.org/content/10.1101/696401v2">Link</a></p><p><b>Date:</b> 2019-07-09</p><p><b>Authors:</b> Kyle E. Landgraf ... Kaman Chan Kim</p><p><b>Downloads:</b> 723</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> We have developed a chimeric antigen receptor (CAR) platform that functions as a modular system to address limitations of current CAR therapies.  An inert form of the NKG2D extracellular domain (iNKG2D) was used as the ectodomain of the CAR to generate convertibleCAR-T cells.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Accurate targeted long-read DNA methylation and hydroxymethylation sequencing with TAPS.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32127008">Link</a></p><p><b>Date:</b> 03/04/2020</p><p><b>Authors:</b> Yibin Liu ...  Chun-Xiao Song</p><p><b>Journal:</b> Genome Biol.</p><p><b>IF (7 or above):</b> 12.16</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> We present long-read Tet-assisted pyridine borane sequencing (lrTAPS) for targeted base-resolution sequencing of DNA methylation and hydroxymethylation in regions up to 10Â kb from nanogram-level input.  Compatible with both Oxford Nanopore and PacBio Single-Molecule Real-Time (SMRT) sequencing, lrTA ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma</h4><p><a href="https://www.biorxiv.org/content/10.1101/642934v1">Link</a></p><p><b>Date:</b> 2019-05-20</p><p><b>Authors:</b> Mahboubeh Yazdanifar ... Pinku Mukherjee</p><p><b>Downloads:</b> 316</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptor engineered T cells (CAR T cells) have shown remarkable success in treating hematologic cancers.  However, this efficacy has yet to translate to treatment in solid tumors.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Metabolism of pancreatic cancer: paving the way to better anticancer strategies.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32122374">Link</a></p><p><b>Date:</b> 03/03/2020</p><p><b>Authors:</b> Cheng Qin ...  Yupei Zhao</p><p><b>Journal:</b> Mol. Cancer</p><p><b>IF (7 or above):</b> 11.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Pancreatic cancer is currently one of the most lethal diseases.  In recent years, increasing evidence has shown that reprogrammed metabolism may play a critical role in the carcinogenesis, progression, treatment and prognosis of pancreatic cancer.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Chlorotoxin Redirects Chimeric Antigen Receptor T Cells for Specific and Effective Targeting of Glioblastoma</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.24.918888v1">Link</a></p><p><b>Date:</b> 2020-01-25</p><p><b>Authors:</b> Dongrui Wang ... Christine E. Brown</p><p><b>Downloads:</b> 194</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> While chimeric antigen receptor (CAR) T cells have demonstrated antitumor activity against glioblastoma (GBM), tumor heterogeneity remains a critical challenge.  To more effectively target heterogeneous GBMs, we report the development of a novel peptide-based CAR exploiting the GBM-binding potential of chlorotoxin (CLTX).</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.30.926535v1">Link</a></p><p><b>Date:</b> 2020-01-30</p><p><b>Authors:</b> Yvette Robbins ... Clint T. Allen</p><p><b>Downloads:</b> 187</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy.  This approach may still be limited by the presence of immunosuppressive myeloid populations.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Perfect adaptation of CD8+ T cell responses to constant antigen input over a wide range of affinity is overcome by costimulation</h4><p><a href="https://www.biorxiv.org/content/10.1101/535385v2">Link</a></p><p><b>Date:</b> 2019-01-30</p><p><b>Authors:</b> Nicola Trendel ... Omer Dushek</p><p><b>Downloads:</b> 704</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Maintaining and limiting T cell responses to constant antigen stimulation is critical to control pathogens and maintain self-tolerance, respectively.  Antigen recognition by T cell receptors (TCRs) induces signalling that activates T cells to produce cytokines and also leads to the downregulation of surface TCRs.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Functionalized microcarriers improve T cell manufacturing by facilitating migratory memory T cell production and increasing CD4/CD8 ratio</h4><p><a href="https://www.biorxiv.org/content/10.1101/646760v1">Link</a></p><p><b>Date:</b> 2019-05-23</p><p><b>Authors:</b> Nathan J. Dwarshuis ... Krishnendu Roy</p><p><b>Downloads:</b> 622</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Adoptive cell therapies (ACT) using chimeric antigen receptor (CAR) T cells have shown promise in treating cancer, but manufacturing large numbers of high quality cells remains challenging.  Critically, current T cell expansion technologies only partially recapitulate the in vivo microenvironment found in the human lymph nodes.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Identification of human CD4+ T cell populations with distinct antitumor activity</h4><p><a href="https://www.biorxiv.org/content/10.1101/2019.12.31.891317v1">Link</a></p><p><b>Date:</b> 2020-01-02</p><p><b>Authors:</b> Michelle H. Nelson ... Chrystal M. Paulos</p><p><b>Downloads:</b> 438</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> How naturally arising human CD4+ T helper subsets impact tumor immunity is unknown.  We reported that human CD4+CD26high T cells elicit potent immunity against solid tumor malignancies.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Three-Compartment Model of CAR T-cell Immunotherapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/779793v1">Link</a></p><p><b>Date:</b> 2019-09-24</p><p><b>Authors:</b> Brendon de Jesus Rodrigues ... Regina C. Almeida</p><p><b>Downloads:</b> 376</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immunotherapy has gained great momentum with CAR T (chimeric antigen receptor) cellular therapy, in which the patients T lymphocytes are genetically manipulated to recognize tumor-specific antigens to increase elimination efficiency.  Although recently approved by FDA to treat B cell malignancies, issues such as dose, administration protocol, toxicity, resistance to immunotherapy, among others, remain open and are the subject of intense research nowadays.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Feasibility of real-time in vivoÂ 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging</h4><p><a href="https://www.biorxiv.org/content/10.1101/789727v1">Link</a></p><p><b>Date:</b> 2019-10-01</p><p><b>Authors:</b> Suk Hyun Lee ... Jin-Sook Ryu</p><p><b>Downloads:</b> 110</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Introduction: Chimeric antigen receptor (CAR) T-cells have been developed recently, producing impressive outcomes in patients with hematologic malignancies.  However, there is no standardized method for cell trafficking and in vivo CAR T-cell monitoring.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.17.909895v1">Link</a></p><p><b>Date:</b> 2020-01-17</p><p><b>Authors:</b> Jason Lohmueller ... Olivera J. Finn</p><p><b>Downloads:</b> 322</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively.  To expand the targeting capabilities of these receptors, we have developed switchable adaptor receptor systems for which receptor specificity can be directed post-translationally via covalent attachment of a co-administered antibody.</p></div></td></div><td></td></tr></table></div><hr></div></body></html>